The NPM1-mutated-specific immune responses, in some cases observed more than 5 years after the completion of anti-leukemic treatments, may have a central role in the favorable outcome registered in NPM1mut/FLT3-ITDnegversus NPM1 non-mutated AML patients. This evidence concerns the gene FLT3 and acute myeloid leukemia.